SELECT PUBLICATIONS

Baum M et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359(9324):2131-9. Abstract

Clarke M et al; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366(9503):2087-106. Abstract

Dixon JM et al. Neoadjuvant tamoxifen and aromatase inhibitors: Comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003;86(3-5):295-9. Abstract

Dixon JM et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001;66(3):191-9. Abstract

Dixon JM et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 2000;6(6):2229-35. Abstract

Dixon JM et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999;6(2):227-30. Abstract

Fisher B et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169):1993-2000. Abstract

Hughes KS et al; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351(10):971-7. Abstract

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract

Vogel VG et al. National Surgical Adjuvant Breast and Bowel Project update: Prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 2003:9(1 Pt 2):495-501. Abstract